Janux Therapeutics, Inc. (NASDAQ:JANX) Major Shareholder Ventures Xi L.P. Avalon Sells 958 Shares

Janux Therapeutics, Inc. (NASDAQ:JANX) major shareholder Ventures Xi L.P. Avalon sold 958 shares of the business’s stock in a transaction on Monday, September 30th. The shares were sold at an average price of $46.24, for a total value of $44,297.92. Following the sale, the insider now owns 6,887 shares in the company, valued at $318,454.88. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Ventures Xi L.P. Avalon also recently made the following trade(s):

• On Friday, September 27th, Ventures Xi L.P. Avalon sold 49,231 shares of Janux Therapeutics stock. The shares were sold at an average price of $46.45, for a total value of $2,286,779.95.
• On Thursday, September 12th, Ventures Xi L.P. Avalon sold 158,031 shares of Janux Therapeutics stock. The stock was sold at an average price of $47.00, for a total transaction of $7,427,457.00.
• On Friday, September 6th, Ventures Xi L.P. Avalon sold 108,365 shares of Janux Therapeutics stock. The stock was sold at an average price of $42.00, for a total transaction of $4,551,330.00.
• On Monday, September 9th, Ventures Xi L.P. Avalon sold 2,182 shares of Janux Therapeutics stock. The shares were sold at an average price of $42.33, for a total transaction of $92,364.06.

Janux Therapeutics Price Performance

Janux Therapeutics stock traded down $0.82 during mid-day trading on Monday, hitting $45.43. The company’s stock had a trading volume of 879,722 shares, compared to its average volume of 722,238. Janux Therapeutics, Inc. has a 12 month low of $5.65 and a 12 month high of $65.60. The business has a 50 day moving average price of $43.92 and a 200-day moving average price of $44.59. The stock has a market cap of $2.36 billion, a price-to-earnings ratio of -37.24 and a beta of 3.57.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.20. Janux Therapeutics had a negative net margin of 291.17% and a negative return on equity of 8.78%. The business had revenue of $8.90 million for the quarter, compared to analysts’ expectations of $0.77 million. The company’s revenue for the quarter was up 709.1% on a year-over-year basis. On average, equities research analysts expect that Janux Therapeutics, Inc. will post -1.18 earnings per share for the current fiscal year.

Institutional Trading of Janux Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Summit Securities Group LLC bought a new stake in Janux Therapeutics during the second quarter worth about $29,000. Amalgamated Bank raised its stake in Janux Therapeutics by 61.1% during the second quarter. Amalgamated Bank now owns 970 shares of the company’s stock valued at $41,000 after buying an additional 368 shares during the last quarter. Plato Investment Management Ltd bought a new stake in Janux Therapeutics in the second quarter worth $42,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Janux Therapeutics in the second quarter worth $151,000. Finally, AQR Capital Management LLC bought a new position in shares of Janux Therapeutics during the second quarter valued at $215,000. 75.39% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

JANX has been the topic of a number of recent analyst reports. Scotiabank lowered their price objective on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a research report on Friday, August 9th. HC Wainwright reaffirmed a “buy” rating and issued a $63.00 price target on shares of Janux Therapeutics in a report on Monday, August 19th. Wedbush restated an “outperform” rating and issued a $74.00 price objective on shares of Janux Therapeutics in a research report on Thursday, August 8th. Cantor Fitzgerald reiterated an “overweight” rating and set a $100.00 target price on shares of Janux Therapeutics in a research report on Monday, September 16th. Finally, Stifel Nicolaus assumed coverage on shares of Janux Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $70.00 price objective for the company. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, Janux Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $66.13.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.